Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Neoadjuvant Locally Advanced Thyroid Cancer
NCT01709292Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vemurafenib in papillary thyroid cancer (PTC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Percent Change in ERK (Extracellular-Signal-Regulated Kinase) Phosphorylation at 56 days and Percent Change in Tumor Size at 56 days. Started Nov 2012; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NCT01709292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709292.